drugset
drugset / Trial / NCT03698305

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

NCT03698305 ↗

Phase 1 Completed 30 enrolled Astellas Pharma Global Development, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to assess the safety and tolerability of ASP5354 administered intravenously as a single dose to healthy subjects. This study will also assess the single dose pharmacokinetics of ASP5354 in plasma and urine.

Timeline

Start
2018-10-25
Primary completion
2019-05-20
Completion
2019-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject pudexacianinium Diagnostic / imaging agent — Intravenous

Indications

No indication recorded.